CU24723B1 - Composición farmacéutica que comprende el ghrp-6 - Google Patents
Composición farmacéutica que comprende el ghrp-6Info
- Publication number
- CU24723B1 CU24723B1 CU2021000010A CU20210010A CU24723B1 CU 24723 B1 CU24723 B1 CU 24723B1 CU 2021000010 A CU2021000010 A CU 2021000010A CU 20210010 A CU20210010 A CU 20210010A CU 24723 B1 CU24723 B1 CU 24723B1
- Authority
- CU
- Cuba
- Prior art keywords
- pharmaceutical composition
- ghrp
- concentration
- composition including
- pharmaceutical
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- WZHKXNSOCOQYQX-FUAFALNISA-N (2s)-6-amino-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-amino-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CN=CN1 WZHKXNSOCOQYQX-FUAFALNISA-N 0.000 title 1
- 108010015153 growth hormone releasing hexapeptide Proteins 0.000 title 1
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 abstract 1
- 102100033367 Appetite-regulating hormone Human genes 0.000 abstract 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 abstract 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 abstract 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 108010077689 gamma-aminobutyryl-2-methyltryptophyl-2-methyltryptophyl-2-methyltryptophyl-lysinamide Proteins 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229940095064 tartrate Drugs 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
<p>La presente invención está comprendida en el campo de las ciencias farmacéuticas. Se refiere a una composición farmacéutica que comprende el péptido liberador de la hormona de crecimiento 6 (GHRP-6) a concentración entre 1.0 mg/mL y 10.0 mg/mL, tampón tartrato a concentración entre 10 .0 mmol/L y 100.0 mmol/L (pH 5.0 – 6.0) y trehalosa a concentración entre 2.0 y 10.0% (m/v), así como el uso de esta composición para la fabricación de un medicamento. La composición farmacéutica referida es aplicable en la industria farmacéutica para uso terapéutico en humanos.</p>
Priority Applications (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU2021000010A CU24723B1 (es) | 2021-01-29 | 2021-01-29 | Composición farmacéutica que comprende el ghrp-6 |
| CA3209594A CA3209594A1 (en) | 2021-01-29 | 2022-01-27 | Pharmaceutical composition containing ghrp-6 |
| MX2023009034A MX2023009034A (es) | 2021-01-29 | 2022-01-27 | Composicion farmaceutica que comprende el ghrp-6. |
| EP22717716.9A EP4285891B1 (en) | 2021-01-29 | 2022-01-27 | Pharmaceutical composition containing ghrp-6 |
| ES22717716T ES3035023T3 (en) | 2021-01-29 | 2022-01-27 | Pharmaceutical composition containing ghrp-6 |
| US18/274,955 US20240139105A1 (en) | 2021-01-29 | 2022-01-27 | Pharmaceutical composition containing ghrp-6 |
| CN202280022883.9A CN117083056A (zh) | 2021-01-29 | 2022-01-27 | 包含ghrp-6的药学组合物 |
| JP2023545946A JP7650993B2 (ja) | 2021-01-29 | 2022-01-27 | Ｇｈｒｐ－６を含有する医薬組成物 |
| PCT/CU2022/050001 WO2022161554A1 (es) | 2021-01-29 | 2022-01-27 | Composición farmacéutica que comprende el ghrp-6 |
| ZA2023/07499A ZA202307499B (en) | 2021-01-29 | 2023-07-27 | Pharmaceutical composition containing ghrp-6 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU2021000010A CU24723B1 (es) | 2021-01-29 | 2021-01-29 | Composición farmacéutica que comprende el ghrp-6 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CU20210010A7 CU20210010A7 (es) | 2022-09-08 |
| CU24723B1 true CU24723B1 (es) | 2024-12-09 |
Family
ID=81346115
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU2021000010A CU24723B1 (es) | 2021-01-29 | 2021-01-29 | Composición farmacéutica que comprende el ghrp-6 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240139105A1 (es) |
| EP (1) | EP4285891B1 (es) |
| JP (1) | JP7650993B2 (es) |
| CN (1) | CN117083056A (es) |
| CA (1) | CA3209594A1 (es) |
| CU (1) | CU24723B1 (es) |
| ES (1) | ES3035023T3 (es) |
| MX (1) | MX2023009034A (es) |
| WO (1) | WO2022161554A1 (es) |
| ZA (1) | ZA202307499B (es) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005200879B2 (en) * | 1999-06-30 | 2007-01-25 | Merck Serono Sa | GRF-containing lyophilized pharmaceutical compositions |
| EP1768647B1 (en) * | 2004-06-17 | 2012-08-08 | Virun, Inc. | Compositions comprising a mucoadhesive protein and an active principle for mucosal delivery of said agent |
| CN101998965B (zh) * | 2007-11-01 | 2014-03-12 | 安斯泰来制药有限公司 | 免疫抑制性多肽与核酸 |
| WO2015200324A1 (en) * | 2014-06-25 | 2015-12-30 | Glaxosmithkline Llc | Pharmaceutical compositions |
-
2021
- 2021-01-29 CU CU2021000010A patent/CU24723B1/es unknown
-
2022
- 2022-01-27 JP JP2023545946A patent/JP7650993B2/ja active Active
- 2022-01-27 US US18/274,955 patent/US20240139105A1/en active Pending
- 2022-01-27 CA CA3209594A patent/CA3209594A1/en active Pending
- 2022-01-27 MX MX2023009034A patent/MX2023009034A/es unknown
- 2022-01-27 CN CN202280022883.9A patent/CN117083056A/zh active Pending
- 2022-01-27 WO PCT/CU2022/050001 patent/WO2022161554A1/es not_active Ceased
- 2022-01-27 EP EP22717716.9A patent/EP4285891B1/en active Active
- 2022-01-27 ES ES22717716T patent/ES3035023T3/es active Active
-
2023
- 2023-07-27 ZA ZA2023/07499A patent/ZA202307499B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4285891B1 (en) | 2025-04-23 |
| CU20210010A7 (es) | 2022-09-08 |
| US20240139105A1 (en) | 2024-05-02 |
| JP7650993B2 (ja) | 2025-03-25 |
| JP2024504462A (ja) | 2024-01-31 |
| CN117083056A (zh) | 2023-11-17 |
| MX2023009034A (es) | 2023-08-09 |
| WO2022161554A4 (es) | 2022-10-13 |
| WO2022161554A1 (es) | 2022-08-04 |
| EP4285891A1 (en) | 2023-12-06 |
| CA3209594A1 (en) | 2022-08-04 |
| ES3035023T3 (en) | 2025-08-28 |
| ZA202307499B (en) | 2024-04-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2019002478A1 (es) | Formulación de anticuerpo monoclonal anti-vrs. | |
| PE20130589A1 (es) | Composiciones y metodos para suministro al sistema nervioso central de arilsulfatasa a | |
| AR079746A1 (es) | Formulacion farmaceutica de anticuerpo | |
| CU20190015A7 (es) | Formulaciones de anticuerpos inhibidores de masp-2 altamente concentrados, de baja viscosidad y composiciones farmacéuticas que las comprenden | |
| PE20191492A1 (es) | Composicion farmaceutica que comprende selexipag | |
| CO2022011728A2 (es) | Composiciones y usos de glp-1 | |
| AR108631A1 (es) | Formulación de neurotoxinas | |
| ECSP077324A (es) | Amidas bicíclicas como inhibidores de cinasa | |
| PH12020551118A1 (en) | Modified lipidated relaxin b chain peptides and their therapeutic use | |
| AR130003A1 (es) | Derivados de piperidinilpiridinilcarbonitrilo como inhibidores de glutaminil-péptido ciclotransferasa y proteína tipo glutaminil-péptido ciclotransferasa | |
| CL2022001035A1 (es) | Composiciones y métodos para minimizar la pérdida de proteínas a concentraciones de proteínas bajas | |
| PE20142275A1 (es) | Formulacion de anticuerpo il-17 | |
| AR115713A1 (es) | FORMULACIÓN ESTABLE DE ALTA CONCENTRACIÓN PARA ANTICUERPOS ANTI-FXIa | |
| AR114323A1 (es) | Péptidos de la cadena b de la relaxina modificados y su uso terapéutico | |
| MX390044B (es) | Derivados de naftiridinona y su uso en el tratamiento de la arritmia. | |
| PE20250835A1 (es) | Composiciones y uso de la tirzepatida | |
| CU24723B1 (es) | Composición farmacéutica que comprende el ghrp-6 | |
| CL2012003119A1 (es) | Composicion farmaceutica para inyeccion que compende una solucion acuosa de ibuprofeno y trometamol, en que la concentracion de ibuprofeno esta entre 2 y 6 mg/ml, la concentracion de trometamol esta entre 1.8 y 5.8 mg/ml, y el ph esta entre 7,0 y 9,5; y su uso para el tratamiento del dolor, la inflamacion o la fiebre. | |
| MX2022008748A (es) | Administración oral de péptidos. | |
| CO2023002650A2 (es) | Formas farmacéuticas sólidas de palbociclib | |
| CO2025007339A2 (es) | Compuesto bicíclico fusionado | |
| MX2023004516A (es) | Uso de pridopidina y analogos para el tratamiento de la ansiedad y la depresion. | |
| AR125470A1 (es) | Composición farmacéutica de pembrolizumab y su uso | |
| BR112019024804A2 (pt) | compostos bicíclicos 5,6-fundidos e composições para o tratamento de doenças parasíticas | |
| DOP2024000096A (es) | Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno |